Objective: To assess the efficacy and safety of bosentan as an adjuvant therapy of persistent pulmonary hypertension of the newborn (PPHN).
Introduction
Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of acute respiratory failure, which is characterized by severe hypoxemia after birth; an absence of cyanotic congenital heart disease; marked pulmonary hypertension; and vasoreactivity with extrapulmonary right-to-left shunting of blood across the ductus arteriosus and/or foramen ovale. 1 It is a common problem in the neonate and is associated with significant morbidity and mortality. 1, 2 Abnormal pulmonary vasoreactivity due to decreased production or responsiveness to vasodilator stimuli and/or increased production or responsiveness to vasoconstrictor stimuli is involved in the pathogenesis of PPHN. 3 Endothelin pathway has a major role in the pathogenesis of PPHN. [4] [5] [6] Increased endothelin-1 plasma concentration was found in newborn infants with PPHN. 7 Inhaled nitric oxide (iNO) is important selective pulmonary vasodilator that has dramatically improved survival. iNO and extracorporeal membrane oxygenation (ECMO) have been widely used as effective treatment modalities of PPHN in developed countries. 3 Mortality varies from 10 to 20% of affected newborns in the developed countries, but is much higher when the above reported therapies are not available. 8 In large parts of the world, particularly in developing countries, iNO and ECMO are not readily available due to high costs and lack of a sufficient infrastructure. Alternative (less expensive) treatments are being sought and bosentan, an oral dual endothelin-1 receptor antagonist, may be an option for the treatment of PPHN. 9 Bosentan has been established in two double-blind, placebo-controlled studies in adults with pulmonary hypertension. 10, 11 A preliminary experience has been described in children over 3 years of age. 12 Bosentan has had limited use in neonates with PPHN. To our knowledge, only four case reports in the literature have documented using bosentan in neonates with PPHN. 9, 13, 14 This study was designed to assess the efficacy, safety and tolerability of bosentan as an adjuvant therapy for neonates with PPHN.
Methods
A prospective, randomized, double-blind, placebo-controlled trial was performed at the neonatal intensive care unit of Abha General Hospital, Saudi Arabia, between September 2008 and January 2011. The study was approved by the ethics committee of the Hospital. Written informed consent was obtained for each patient before enrollment.
Study design
Neonates with gestational ages X34 weeks who were <7 postnatal days of age were enrolled in the study if they met the following criteria: (1) mechanical ventilation and fraction of inspired oxygen >0.50;. and (2) pulmonary hypertension confirmed by echocardiogram. The diagnosis of PPHN is made by characteristic lability in oxygenation state of the infant or progressive cyanosis within the first 12 to 24 h of life, echocardiographic evidence of increased pulmonary pressure, with demonstrable shunts across the ductus arteriosus or foramen ovale and the absence of cyanotic heart disease lesions. 15 The echocardiogram performed before enrollment had to show evidence of right-to-left shunt and estimated pulmonary artery pressures X40 mm Hg. Infants who had cyanotic congenital heart diseases, congenital malformations, bleeding tendency or elevated serum bilirubin, liver enzymes and alkaline phosphatase were excluded.
Patient assignment
Patients with PPHN were randomly assigned to receive either bosentan or placebo according to a schedule generated by computer to ensure equivalent randomization. The schedule was maintained by the participating pharmacist. The investigator and treating nurses were unaware of the treatment assignments. The bonstan solution was prepared from a 125-mg tablet, which was crushed to one-fourth and then dissolved in sterile water of 10 ml (3 mg in 1 ml). Bosentan (1 mg kg À1 twice a day) or placebo (equal volume of diluent) were administered to the patient via orogastric tube followed by administration of 1 ml sterile water to ensure that the dose was actually delivered to the stomach. Opaque covers were used to cover the drug's container and oro-gastric tubes used for the administration of bosentan or placebo. There are no studies on pharmacokinetics of bosentan in neonatal population, and we have only limited experience with dosages and interval times of bosentan in neonates with PPHN. Therefore, the dose and interval used in this study were based on doses successfully used in the previous studies. 9, 13, 14 Mean arterial pressure, arterial blood gas, oxygenation index (OI), pulse oxygen saturation (SpO 2 ), serum bilirubin, liver enzymes, alkaline phosphatase, serum creatinine and serum electrolytes were determined at the time of enrollment of patients in the study as a baseline assay. Arterial blood gases were monitored from an umbilical arterial catheter, and OI was calculated in every arterial blood gas using the partial pressure of arterial oxygen (PaO 2 ) from the umbilical arterial catheter and the following formula to calculate OI: OI ¼ (fraction of inspired oxygen Â mean airway pressure)/PaO 2 . Arterial blood gases were performed at 0, 2, 4, 6, 12, 18, 24, 30 and 36 h after initiation of treatment then every 8 h till the end of drug therapy. SpO2 and mean arterial pressure were monitored continuously.
In our Hospital, iNO, ECMO and other pulmonary vasodilators are not available. Therefore, in this trial, bosentan or placebo were used alone and not in combination with iNO, ECMO or other pulmonary vasodilators. Clinical management protocols used in the neonatal intensive care unit by attending physicians caring for infants with PPHN were not otherwise altered. The clinical approach for all of the infants included: no 'hyperventilation' but avoidance of hypercarbia (that is, PaCO 2 (partial pressure of arterial carbon dioxide): 35 to 50 mm Hg), avoidance of significant acidosis, (that is, maintain pH >7.30), no alkalosis (that is, not aiming to keep pH >7.45), inotropes (dopamine and dobutamine) and volume infusion to preserve intravascular volume and maintain mean arterial pressure X50th percentile. Discontinuation of bosentan or placebo was done according to one of two criteria, whichever occurred earlier: (1) three successive measurements of OI were <15 in addition to normal pulmonary artery pressure (<20 mm Hg) or (2) maximum period of 7 days treatment. At the end of the study therapy, all patients were eligible to enter an open-label study of bosentan.
Primary (drug) outcome
The efficacy and safety of bosentan therapy were evaluated at three time points (on day 3 of drug therapy, at the end of drug therapy and at 2 weeks after discontinuation of drug therapy).
Evaluation of efficacy
Efficacy was assessed according to the overall response to treatment. The outcome was considered favorable if all the following three criteria were met: OI <15, normal pulmonary artery pressure (<20 mm Hg), and no premature discontinuation of the drug because of lack of efficacy or drug-related toxicity. Lack of efficacy was defined as no significant change in OI (a decrease in OI of more than 10% from the previous calculated value) after 36 h of treatment or persistent high pulmonary artery pressure. The main outcome variable was the effect of bosentan on OI values. OI was measured at 0, 2, 4, 6, 12, 18, 24, 30 and 36 h after initiation of bosentan, every 8 h till the end of drug therapy and at the three time points of assessment. Pulmonary artery pressure was measured before enrollment, when OI reached <15 and at the three time points of assessment.
Evaluation of safety
The evaluation of safety and tolerability of bosentan was assessed by review of all study adverse events. Patients were monitored for clinical adverse events (hypotension, gastric intolerance, bleeding or pulmonary hemorrhage) daily during the administration of study therapy and for 14 days thereafter. Serum bilirubin, liver enzymes, alkaline phosphatase, serum creatinine, serum electrolytes and complete blood count were performed thrice weekly throughout the drug therapy and at follow-up visits (2 weeks and 6 months after treatment). The outcome was considered unfavorable if the study drug was withdrawn due to clinical and or laboratory drug-related adverse events. Abnormal liver functions were defined as lactate dehydrogenase >1.5 times the upper limit of normal; alanine aminotransferase and/or aspartate aminotransferase >3 times the upper limit of normal.
A nephrotoxic effect was defined as serum creatinine levels that was twice the baseline value or higher. Secondary (disease) outcome PPHN outcome was evaluated at 6 months after treatment. PPHN major sequelae included the incidence of death (<28 days), neurologic sequelae, bronchopulmonary dysplasia and reactive airway disease. Neurologic sequelae were defined as clinical or electroencephalogram-proven seizures, abnormalities in muscle tone, deep tendon reflexes, delay in motor milestone or abnormal auditory brain stem response (ABR). At 6 months after the end of study therapy, the following tests were performed for neurologic evaluation: electroencephalogram, cranial magnetic resonance imaging study and ABR, which was measured using Neuropack 8 (Nihon Koden, Tokyo, Japan). Cranial magnetic resonance imaging was also performed before the initiation of drug therapy as a baseline study. ABR abnormalities were defined as (1) Bronchopulmonary dysplasia (for infants '32 weeks post-menstrual age at birth) was defined as the need for supplemental oxygen at 56 days postnatal age, or at discharge whichever comes first. 16 Reactive airway disease was defined as frequent wheezing episodes that required chronic bronchodilator therapy or hospital admission. 17 The clinical records of all patients during the 6 months after treatment were reviewed for the development of bronchopulmonary dysplasia or reactive airway disease.
Sample size and statistical analysis
The sample size was determined based on the incidence of PPHN in our area, which was estimated before the start of this trial in a retrospective study. The confidence level of sample size was 95% and the confidence interval was 4%. Indices of efficacy and safety of bosentan were expressed as frequencies and proportions. Chi-square, Fisher's exact, and Student's t-test tests were used as tests of significance at the 5% level. Statistical analysis was performed using SPSS version 10.0 program for windows (SPSS Inc., Chicago, IL, USA) software. 
Results
Of 52 newborn infants with PPHN recruited, 47 were included in the study, 24 were assigned to receive bosentan and 23 were assigned to receive placebo. Five patients were excluded because they did not meet all the entry criteria ( Figure 1) . Of the 47 patients, 26 (55.3%) infants had meconium aspiration syndrome, 9 (19.2%) had premature rupture of membranes, 7 (14.9%) had hyaline membrane disease and 5 (10.6%) had idiopathic PPHN. The bosentan and placebo groups were well matched with respect to clinical and baseline characteristics ( Table 1) .
Efficacy
At the time of entry, the mean OI was 43.6±4 in the bosentantreatment group and 45.1 ± 3 in the placebo group (P>0.05). The baseline PaO 2 values in the two groups were 38.3±4 mm Hg and 36.1 ± 5 mm Hg, respectively (P>0.05). Bosentan induced significant improvement (P<0.05) in OI and SpO 2 compared with the baseline and with the placebo group at 6 h after initiation of treatment and thereafter. Figures 2 and 3 show the changes in OI and SpO 2 after bosentan and placebo administration. Following discontinuation of bosentan, the mean OI was 12.3 ± 1 and SpO 2 was 92.2±0.9. No evidence of rebound hypoxemia was detected in any of the infants in whom bosentan was discontinued because of achievement of the prespecified improvement in OI (that is, OI <15). In the bosentan-treated group, the duration of mechanical ventilation was significantly lower than that of placebo group (4.3 ± 0.9, 11.5 ± 0.6 days, respectively; P<0.001). At the end of study therapy, the efficacy of bosentan as adjuvant treatment was significantly higher than that of placebo group, with favorable outcomes in 87.5% of patients treated with bosentan and in 20% of those received placebo (P<0.0001). At each of the three time points None of the differences between the treatment groups were statistically significant. of evaluation of efficacy, the percentage of patients with favorable responses was significantly higher in the bosentan group than in the placebo group. After day 3 of study therapy, eight patients in the placebo group withdrew from subsequent evaluation due to clinical worsening. This apparent crossover may complicate interpretation of the data. No clinical worsening was reported in patients given bosentan (Table 2) . Patients in the bosentan group were treated with study therapy for a mean of 4.8 ± 1.1 days (median 5 days; range: 3 to 7 days).
Safety and tolerability
The oro-gastric administration of the prepared solution was simple and easily accomplished, and the doses were equally well tolerated in the bosentan and placebo groups. None of patients in the bosentan group had drug-related clinical or laboratory adverse events.
Secondary outcome (PPHN major sequelae) At 6 months follow-up visit, 23 infants in the bosentan group and 14 infants in the placebo group were analyzed for the disease outcome (Figure 1 ). Overall PPHN major sequelae was significantly lower in the bosentan group than in the placebo group (P ¼ 0.0008). Four patients died, one in the bosentan group and three in the placebo group (P ¼ 0.14). The infant who died in the bosentan group did so at 17 days of age because of premature rupture of membranes and pulmonary hypoplasia. In the placebo group, infants died at 5, 7 and 10 days of age with refractory hypoxemia and pulmonary hypertension secondary to meconium aspiration syndrome.
Four (28.5%) infants with PPHN in placebo group had neurologic sequelae, however, all infants in the bosentan group had normal neurologic assessment (P ¼ 0.01). Of the four infants who had neurologic sequelae, three had delayed motor development, spasticity and hyperreflexia, and one infant had abnormal ABR. Abnormal electroencephalogram and cranial magnetic resonance imaging were detected in all of those patients compared with normal baseline studies before starting bosentan treatment (Table 3) .
Discussion
PPHN is a life-threatening condition, being among the most rapidly progressive and potentially fatal form of vasculopathies. 18 Despite the recent advances, the clinical approach to PPHN still represents an important challenge for neonatologists. The care of newborns with PPHN requires meticulous therapeutic and ventilation strategies including, besides the stabilization of the newborn, the use of high frequency ventilation, iNO and ECMO. However, not all the neonates with PPHN are responsive to this clinical approach. Approximately 30% of patients fail to respond to iNO. Nitric oxide and ECMO are costly and may not be appropriate in resource-poor settings. 19 High plasma concentration of endothelin-1 in newborn infants with PPHN 7 has led to the use of endothelin-1 receptor antagonist such as bosentan for the treatment of PPHN.
To the best of our knowledge, this is the first reported prospective, randomized, double-blind clinical trial than was designed to assess the efficacy, safety and tolerability of bosentan in newborn infants with PPHN although not the first report use of bosentan in newborn infants with PPHN. Previous published experience consists only of four case reports. Nakwan N et al. 9 reported an effective use of bosentan alone as an alternative treatment of PPHN in a full-term neonate. Goissen et al. 13 reported a successful use of bosentan as an adjunct therapy to iNO and sildenafil in two newborns with PPHN complicating transposition of the great arteries. Radicioni et al.
14 reported a successful combination therapy of bosentan, iNO and sildenafil in a preterm infant with life-threatening PPHN after premature rupture of membranes.
At the end of oral therapy, our results showed that bosentan was more effective adjuvant treatment for PPHN in neonates than placebo. Also at each time point of evaluation of efficacy, bosentan was superior to placebo. In bosentan-treated group, no premature a The differences between the treatment groups were statistically significant. The primary time point for determination of efficacy was the end of oral study therapy. discontinuation of bosentan due to lack of efficacy or clinical worsening was observed. All infants who received bosentan showed significant improvement in oxygenation at 6 h after initiation of treatment. Moreover, the duration of mechanical ventilation was significantly decreased compared with placebo group. We did not detect any clinical or laboratory adverse events potentially secondary to bosentan treatment. Bosentan appears to manifest favorable efficacy and safety profiles in newborn infants. Efficacy and safety of bosentan in our patients are consistent with those previously described for this treatment in neonates. 9, 13, 14 Infants with PPHN who survived are at a high risk for neurodevelopmental abnormalities including hearing impairment both because of the nature of this illness and hypoxemia. 20, 21 At 6-month follow-up evaluation, the overall PPHN major sequelae was significantly lower in infants treated with bosentan than in those given placebo. None of infants in the bosentan-treated group had neurologic sequelae. Of 24 bosentan-treated neonates, only 1 infant died. This finding suggests that oral bosentan may be associated with increased survival in cases of PPHN in areas where resources like iNO and ECMO are unavailable.
Conclusion
Oral bosentan performed better than the placebo. Bosentan may be a useful adjuvant therapy in neonates with PPHN in centers lacking iNO and ECMO. Our study has important limitations that require consideration. First, the number of subjects was relatively low and thus the safety conclusions remain tentative as less frequent but severe adverse effects cannot be excluded based on this study. Therefore, further controlled, multicenter studies with larger sample sizes should be undertaken. Second, this study assessed the efficacy of bosentan alone and did not compare its effectiveness in relation to other treatment methods so further trials to compare bosentan with other methods are needed. Also in future studies, pharmacokinetics and optimal dosing of bosentan in neonates need to be determined.
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